sign in sign up
<<
Home , Nocardicin A

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 25 * JUNE 1984 NUMBER 6 Leon H. Schmidt, Editor in Chief (1985) George A. Jacoby, Jr., Editor (1985) University ofAlabama in Birmingham Massachusetts General Hospital Birmingham Boston Herbert L. Ennis, Editor (1987) Robert C. Moellering, Jr., Editor (1987) Roche Institute ofMolecular Biology New England Deaconess Hospital Nutley, New Jersey Boston, Massachusetts Robert L. Hamill, Editor (1985) John A. Washington II, Editor (1986) Eli Lilly & Company, Inc. Mayo Clinic Indianapolis, Indiana Rochester, Minnesota Peter G. Welling, Editor (1988) Warner-Lambert Co. Ann Arbor, Michigan EDITORIAL BOARD Norris Allen (1986) Robert J. Fass (1985) Stuart B. Vincent T. Andriole (1984) Stuart Feldman Levy (1986) Merle Sande (1985) John P. Anhalt (1984) (1985) Friedrich C. Luft (1984) Christine C. Sanders (1984) Bascom F. Anthony (1985) Sydney Finegold (1985) Joan Lusk (1986) W. Eugene Sanders (1984) Robert J. Fitzgerald (1986) R. Luthy (1986) W. Michael George R. Aronoff (1986) Martin Forbes (1986) Francis L. Scheld (1986) Robert Austrian (1986) Dale Macrina (1985) Jerome J. Schentag (1985) Richard N. Gerding (1985) Gerald L. (1986) Raymond F. Schinazi H. Baltz (1984) David Gilbert (1984) R. MatzkeMandell (1986) Rashmi H. Barbhaiya (1986) J. Glazko Gary (1986) Fritz D. Schoenknecht (1986) Arthur L. Barry (1986) Anthony (1984) George H. McCracken (1984) F. C. Sciavolino (1985) Irving H. Goldberg (1985) Gerald Medoff (1986) William John D. Bartlett (1984) Richard H. Gustafson (1984) Michael M. Shannon (1986) Michael Barza (1985) Jack Miller (1984) Charles Shipman, Jr. (1985) John E. Bennett (1984) Gwaltney (1986) Barbara Minshew (1985) Robert W. Sidwell (1984) Scott M. Hammer (1986) Bernard Moss (1984) P. Frederick Richard F. Bergstrom (1985) W. Lee Hand (1986) Thomas P. Sparling (1984) Gerald P. Bodey (1986) H. Hunter Moyer (1986) Harold Standiford (1985) Lawrence E. Bryan (1985) Handsfield (1986) Barbara E. Murray (1984) David A. Stevens (1986) Maurice W. Harmon (1984) John D. Nelson (1986) R. Sutherland Ward Bullock (1984) Joseph Hawkins, Jr. (1985) Harold C. (1985) Tsun Chang (1986) Michael Neu (1986) Vera L. Sutter (1984) Anthony Chow (1985) Higgins (1986) James T. Park (1985) Morton N. Swartz (1985) C. Richard Hornick (1986) James E. Pennington (1986) Richard B. Sykes Glenn Cobbs (1986) George Gee Jackson (1986) T. J. Perun (1985) Paul S. Cohen (1986) James H. (1986) Francis P. Tally (1984) William A. Jorgensen (1984) Lance R. Peterson (1985) Alexander Tomasz Craig (1984) William J. Jusko (1986) Burton M. Pogell (1984) (1985) Naomi Datta (1984) A. W. Karchmer (1985) Michael Ralph Tompsett (1985) Lawrence E. Day (1986) Donald Rein (1986) Francis L. S. Tse (1986) William E. Dismukes (1984) Kaye (1985) W. H. G. Richards (1986) Michael Waring (1984) R. George S. Kobayashi (1985) Richard Roberts (1985) Bernard Gordon Douglas, Jr. (1986) Donald J. Krogstad (1986) Ian M. Weisbium (1985) John C. Drach (1984) Felix Rollo (1985) Richard M. Welch (1986) Theodore Leitner (1986) Richard Root (1986) Richard Wise Eickhoff (1985) Stephen A. Lerner (1986) John P. Rosazza (1986) Gertrude B. Elion (1984) Matthew E. Levison (1986) Lowell Young (1985) Arthur English (1986) (1984) Jon E. Rosenblatt (1985) Pauline K. W. Yu (1985)

Helen R. Whiteley, Chairman, Publications Board Walter G. Linda M. Illig, Peter III, Director ofPublications Managing Editor, Journals Deborah J. Shuman, Production Editor Antimicrobial Agents and Chemotherapy (ISSN 1913 I St., NW, 0066-4804), an interdisciplinary publication of the American Society for Microbiology, Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of anticancer agents and chemotherapy. Instructions to authors are published in antimicrobial, antiparasitic, and editors and the Publications Department. the January issue each year; reprints are available from the into two Antimicrobial Agents and Chemotherapy is published monthly, and the twelve numbers are volumes per year. The nonmember subscription price is $157 per year; single copies are divided (foreign, $41 [surface rate]) per year; single copies are $7. $21. The member subscription price is $31 back issues, lost or late Correspondence relating to subscriptions, reprints, defective copies, availability of proofs, disposition of submitted manuscripts, and general editorial matters should be Department, 1913 I St., NW, Washington, DC 20006 (phone: 202 833-9680). directed to the ASM Publications Claims for missing issues from residents of the United States, Canada, and Mexico the issues; residents of all other countries must submit must be submitted within 3 months after publication of of failure to claims within 6 months of publication of the issues. Claims for issues missing report an address change or for issues "missing from files" will not be allowed. because Second-class postage paid at Washington, DC 20006, and at additional mailing offices. POSTMASTER: Send address changes to Antimicrobial Agents and Made in the United States of America. Chemotherapy, ASM, 1913 I St.. NW, Washington, DC 20006. Copyright © 1984, American Society for ii All Rights Reserved. Microbiology. H*: 14ltS* e ;11wl* ( Fl4u. The code at the top of the first page of an made for article in this journal indicates the copyright owner's consent that copies of the article personal use or for personal use of specific clients. This consent is given on the condition, may be per-copy fee through the Copyright Clearance Center, Inc., 21 however, that the copier pay the stated 107 and 108 of the U.S. Copyright Congress St., Salem, MA 01970, for copying beyond that permitted by Sections Law. This consent does not extend to other kinds of copying, such as copying for general advertising or promotional purposes, for creating new collective works, or for resale. distribution, for Author Index

Ackerman, Bruce H., 785 Gotoh, Akira, 754 Malewicz, B., 772 Stachowski, Michael, 778 Actor, Paul, 694 Grappel, Sarah F., 694 Momsen, M., 772 Strikas, Raymond, 778 Apolloni, E., 760 Grossman, Dena M., 690 Morrison, Joan O., 725 Sun, Chong-Son, 729 Arosio, E., 760 Guymon, L. F., 767 Myers, William F., 690 Tannenbaum, Charles S., 673 Baron, Ellen J., 781 Hastie, Annette T., 673 Neu, Harold C., 687 Thornsberry, Clyde, 710 Barry, Arthur L., 710, 775 Higgins, Michael L., 673 Neut, C., 764 Tofte, Robert W., 785 Bayer, Arnold S., 725 Hindler, Janet A., 781 Bedows, Elliott, 719 Benoni, G., 760 Jakas, Dalia R., 694 Parr, Thomas R., Jr., 747 Ubukata, Kimiko, 754 Borowski, E., 772 James, Philip R., 735 Parrillo, Patricia, 778 Bryan, L. E., 747 Jenkin, H. M., 772 Passarella, E., 760 Vaara, M., 701 Jones, Ronald N., 710, 775 Penn, Robert L., 770 Velo, G. P., 760 Campos, Jose, 706 Phillips, Lillian, 694 Verbist, Ludo, 783 Catlin, B. Wesley, 676 King, John W., 770 Pitkin, Donald, 694 Verpooten, Gert A., 783 Chin, Nai-Xun, 687 Knight, Paul R., 719 Pollet, Dirk E., 783 Viljarten, P., 701 Knight, Vernon, 729 Vosbeck, Klaus, 735 Davidson, Bruce A., 719 Kobasa, William D., 683 Raimondi, M. G., 760 Romond, C., 764 De Broe, Marc E., 783 Konno, Masatoshi, 754 Weinbaum, George, 673 Devos, J., 764 Kramer, Michael J., 729 Ross, Janette, 785 Rotschafer, John C., 785 Wilson, Samuel Z., 729 Dubreuil, L., 764 Kueppers, Friedrich, 673 Wisseman, Charles L., Jr., 690 Dunn, George L., 694 Wyde, Philip R., 729 Labthavikul, Pornpen, 687 Sakuma, Takashi, 742 Eisenstadt, Rosalee, 725 Lechi, A., 760 Sanfeliu, Isabel, 706 Lentino, Joseph R., 778 Scharpe, Simon L., 783 Yamashita, Naoko, 754 Garcia-Tornel, Santiago, 706 Levison, Matthew E., 683 Shafer, W. M., 767 Giuliano, Ruben A., 783 Lind, I., 767 Sparling, P. F., 767 Zimmermann, Willy, 735 AUTHOR INDEX VOLUME 25

Ackerman, Bruce H., 785 Bongaerts, Ger P. A., 234 Dotzlaf, Joe E., 216 Glasser, Lynne A., 510 Ackers, Irene, 579 Borner, K., 105 Dromer, Francoise, 168 Glette, Johan, 354 Actor, P., 373 Borobio, M. Victoria, 342 Dubois, Catherine, 168 Gnarpe, H'akan, 179 Actor, Paul, 694 Borowski, E., 772 Dubreuil, L., 764 Godefroy, Isabelle, 168 Adejuyigbe, Olusanya, 497 Borsa, F., 638 Dunn, George L., 694 Godfrey, A. J., 382 Adkinson, N. Franklin, Jr., 93 Bosso, John A., 630 Dworzack, David L., 494 Goessens, Wil H. F., 575 Ahmed, S. Masud, 643 Boutwell, M. E., 650 Dylewski, Joe S., 25 Goldman, Peter, 65 Akhter, S. Q., 643 Bouzos, John, 534 Gombert, Myles E., 510 Albritton, William L., 187, 296 Bright, Gene M., 113 East, Donald S., 83 Gooch, W. Manford, III, 502 Alford, Robert H., 405 Brion, Nils, 168 Eby, George A., 20 Goodman, Larry J., 504 Anderson, Burt, 296 Brook, Itzhak, 71 Echols, Roger M., 336 Gootz, Thomas D., 591 Andreana, Augusto, 182 Brown, Daniel R., 422 Egbert, Peter R., 25 Gordon, Y. Jerold, 522 Andrews, J. M., 612 Brown, Douglas, 286 Eisenstadt, Rosalee, 725 Goto, Sachiko, 98 Andritz, Mary H., 33 Brown, Timothy H., 405 Elion, Gertrude B., 507 Gotoh, Akira, 754 Angehrn, Peter, 607 Brumfitt, W., 276 Eliopoulos, G. M., 331, 401 Goueffon, Y., 463 Apolloni, E., 760 Bryan, C. S., 37 Eliopoulos, George M., 398 Grappel, Sarah F., 694 Arbeter, A. M., 417 Bryan, L. E., 382, 747 Elvers, A., 105 Greenman, Richard L., 16 Arceneaux, Jean E. L., 650 Buesing, Mary A., 283 Ene, Mokelu D., 1 Griffin, Paul E., 33 Arcey, Sergio M., 16 Butler, Thomas, 643 Eng, Robert H. K., 510 Gropen, Toby I., 522 Arndt, Kenneth A., 553 Buu-Hoi, Annie, 289 English, A. R., 118 Grossman, Dena M., 690 Aronoff, George R., 513 Byers, B. R., 650 English, Arthur R., 113, 226, 599 Gruft, Howard, 137 Aronoff, Stephen C., 279 Eppstein, Deborah A., 563 Guay, David R., 306 Arosio, E., 760 Cabezudo, Ignacio, 4 Guenthner, Sharon H., 4 Asahi, Yoshinari, 131 Cable, Douglas C., 258 Fadl-Allah, Nora, 375 Guerrant, Richard L., 653 Ash, Ronald J., 443 Campbell, Gwendolyn S., 205 Fainstein, V., 387 Gutterman, Deborah A., 16 Assael, Baroukh M., 395 Campos, Jose, 706 Falkinham, Joseph O., III, 137 Guymon, L. F., 767 Auerbach, Jeffrey I., 622 Campos, Joseph M., 327 Farber, Bruce F., 398 Auger, Franqois, 662 Carbon, Claude, 168, 618 Fasching, Claudine E., 58, 545, Halcomb, William W., 20 Austin, Thomas W., 455 Cardinal, J. R., 10 596 Hall, Dennis, 571 Ayers, L. W., 633 Carr, Douglas, 539 Fass, Robert J., 408 Hall, Michael J., 607 Ayers, Leona W., 669 Carter, Walker T., 162 Field, A. Kirk, 238, 247 Haller, Ingo, 125 Ayrton, John, 78 Casalino, M., 499 Fillastre, J. P., 638 Halstenson, C. E., 128 Azegami, Masao, 146 Catlin, B. Wesley, 676 Finegold, Sydney M., 162 Halstenson, Charles E., 433, 603 Chan Lee, Huei, 146 Fischer, Philip R., 502 Hamilton-Miller, J. M. T., 276 Baba, Masanori, 515 Chau, Nguyen Phong, 618 Fite, Laurie D., 443 Hammer, Mark C., 33 Baker-Zander, Sharon A., 390 Cheung, Rose, 537 Fliegelman, Robert M., 504 Hansen, Alfred R., 301 Ballard, James O., 153 Chiemchanya, Surang, 273 Florioli, Alessandra, 395 Hansen, Chad S., 301 Baltch, Aldona L., 33, 488 Chin, Nai-Xun, 319, 687 Flynn, Gary A., 443 Hantz, O., 242 Bannatyne, Robert M., 537 Chopra, Ian, 446 Foglesong, Mark A., 216 Harcus, Jane L., 571 Barge, Janine, 168 Chou, Sunwen, 25 Fontijne, P., 575 Harding, Stuart M., 78, 344 Barlam, Tamar, 529 Cohn, Naomi K., 292 Forbes, Betty A., 491 Harris, Betty, 162 Barnes, Scott G., 153 Coleman, William G., Jr., 539 Forthal, Donald N., 258 Harris, Cynthia, 560 Baron, Ellen J., 781 Collins, Shirley H., 301 Fortin, Louise, 83 Harrison, Lester I., 301 Baron, Jody L., 646 Comanducci, A., 499 Fourtillan, Jean-Bernard, 618 Hashizume, Terutaka, 148 Baron, Samuel, 646 Congeni, Blaise L., 40 Frankel, Lawrence S., 62 Haskell, Suzanne L., 599 Barrueco, M., 458 Conroy, Joseph V., 33 Fraser-Smith, Elizabeth B., 563 Hastie, Annette T., 673 Barry, A. L., 633 Contrepois, Alain, 168, 618 Freydiere, A. M., 144 Hayden, Frederick G., 53 Barry, Arthur L., 392, 669, 7110, Coolbaugh, James C., 71 Frongillo, R. F., 666 Hector, Richard F., 596 775 Coppenhaver, Dorian H., 646 Fuchs, Peter C., 392 Heessen, Frans W. A., 123 Bartus, Henry R., 622 Correia, Ricardo A., 653 Funk, Mary L., 301 Herbst, John J., 630 Barza, Michael, 655 Crooke, Stanley T., 622 Furman, Phillip A., 191, 507 Hersh, Evan M., 366 Baxter, Heather, 306 Crossley, Kent B., 532 Hewlett, Erik L., 571 Bayer, Arnold S., 725 Crumpacker, Clyde S., 247, 553 Gangemi, J. D., 37 Higgins, Michael L., 673 Beaulieu, Bernard B., Jr., 65 Culbert, Steve, 62 Garcia-Tornel, Santiago, 706 Hindler, Janet A., 781 Bedows, Elliott, 719 Gardella, A., 331, 401 Hirata, Takahiro, 148, 348 Beggs, William H., 316 Daneshmend, Tawfique K., 1 Gavan, Thomas L., 669 Hoeprich, Paul D., 339 Beight, Douglas W., 443 Davidson, Bruce A., 719 Gaynon, Michael W., 25 Holmes, King K., 390 Belsheim, Judy, 179 Davies, Mary-Ellen M., 238 George, Karen L., 137 Hooper, David C., 586 Benoni, G., 760 Davis, Donald R., 20 George, W. Lance, 657 Hopen, Gunnar, 354 Berens, Randolph L., 292 De Broe, Marc E., 783 Geratz, J. Dieter, 582 Hopfer, R. L., 387 Berliner, Daniel, 7 De Clercq, Erik, 566 Gerding, Dale N., 58, 545, 560 Hopfer, Roy L., 366 Berman, Steven J., 438 DeClercq, Erik, 515 Gerlach, E. H., 633, 669 Horaud, Thea, 289 Bianchi, P., 666 DeGirolami, P., 401 Gerv6s, M. Santiago, 458 Hughes, Carolyn E., 560, 596 Biddle, James, 296 Deneer, Harry G., 187 Giamarellou, Helen, 534 Humbert, G., 638 Bieth, Gilda, 289 Denoya, Claudio D., 659 Gill, Charles J., 327 Abdelrahim 173 Blase, David K., 513 Devlin, Richard G., 358 Gill, M. John, 476 Hunaiti, A., Blevins, Roger D., 603 Devos, J., 764 Gille, Y., 144 Blok-Perkowska, Danuta, 134 Dewsnup, Daniel H., 165 Girard, A. E., 118 Ikeda, Chieko, 221 Blomqvist, Charlotte, 179 Dilillo, Mariantonia, 182 Girard, Dennis, 599 Inaba, Hitoshi, 88 Blumer, Jeffrey L., 579 Diven, Warren, 473 Giuliano, Ruben A., 783 Inoue, Hiroshi, 146 Bondi, Joseph V., 238 Dominguez-Gil, A., 458 Givan, Katherine F., 455 Inoue, Matsuhisa, 362 i ii AUTHORINDEX ANTIMICROB. AGENTS CHEMOTHER.

Isono, Midori, 131 Lewis, John C., 380 Mirabelli, Christopher K., 622 Peterson, Lance R., 58, 545, 560, Ito, Masahiko, 515 Lewis, Michael R., 422 Mitsuhashi, Susumu, 362 5% Li, Edwin L. F., 455 Miyakawa, Isao, 146 Pfaller, Michael A., 368 Jackson, David B., 591 Lin, C., 45 Mobley, Harry L. T., 157 Phillips, Lillian, 694 Jacobs, Michael R., 527 Lind, I., 767 Mochizuki, Hidenori, 88 Pichoud, C., 242 Jacoby, Irving, 626 Lipsky, James J., 380 Moellering, R. C., Jr., 331, 401 Pickering, Larry K., 62 Jacyk, William R., 306 Livelli, Thomas J., 247 Moellering, Robert C., Jr., 398 Pirie, Donald K., 226 Jakas, Dalia R., 694 Livermore, David M., 268 Molendijk, Lucy, 234 Pitkin, Donald, 694 James, Philip R., 735 Lloyd, William J., 607 Momsen, M., 772 Piziak, Myron V., 7 Jenkin, H. M., 772 Lode, H., 105 Montay, G., 463 Plotkin, S. A., 417 Johnson, Elizabeth M., 1 Lolekha, Somsak, 273 Moody, Julia A., 545, 560 Pohlod, Donald J., 377 Johnson, Jonas, 473 Lopez-Berestein, G., 387 Moretti, A., 666 Pollack, Simeon, 375 Johnson, Randall K., 622 Lopez-Berestein, Gabriel, 366 Morgan, S. L., 37 Pollet, Dirk E., 783 Johnson, Steven R., 296 Lorian, Victor, 311 Morgant, Catherine, 618 Porter, F. D., 157 Johnston, Ralph W., 205 Lowy, Franklin D., 375 Mori, Norimasa, 146 Portnoy, David, 455 Jones, R. N., 633 Luft, Friedrich C., 513 Morrison, Joan O., 725 Potten, Michael R., 1 Jones, Ronald N., 392, 669, 710, Lukehart, Shelia A., 390 Muder, Robert R., 473 Preblud, S. R., 417 775 Lundback, Annika, 179 Muller, G., 281 Preblud, Stephen R., 327 Jordan, A. B., 37 Lynch, J. E., 118 Muramatsu, Masatake, 385 Proctor, E. A., 417 Jorgensen, James H., 283 Lyon, James, 473 Murray, Barbara E., 398 Provoost, Abraham P., 497 Juliano, R. L., 387 Murray, Patrick R., 368 Prusoff, William H., 566 Juliano, Rudolph L., 366 Maclean, Ian W., 187 Muytjens, Harry L., 123 Pugsley, Mary P., 494 Mader, Jon T., 139 Muzalewski, Feliks, 134 Pushkarskaya, Nina L., 53 Kabir, Iqbal, 643 Mageau, Richard P., 205 Myers, Carolyn M., 579 Kamimura, Toshiaki, 98 Maimone, F., 499 Myers, William F., 690 Radika, Kesavan, 479 Kanzaki, Masako, 385 Malewicz, B., 772 Rahaman, M. Mujibur, 643 Kaplan, Raymond L., 504 Mandel, Neil, 109 Nagel, Arthur A., 113 Raimondi, M. G., 760 Katz, Ehud, 195 Manian, Albert A., 571 Nakagawa, Keiichi, 221 Rector, Tim M., 582 Katz, W., 253 Margalith, Eva., 195 Nakatsuru, Naoki, 221 Reed, Michael D., 579 Keane, W. F., 128 Marifno, E. L., 458 Nelson, Donald J., 292 Retsema J. A., 118 Keane, William F., 433 Marino, John, 527 Nelson, Erica, 522 Retsema, James A., 113, 226 Kern, Earl R., 553 Marks, Melvin I., 212 Nesburn, Anthony B., 522 Richardson, Malcolm D., 1 Kesado, Tadataka, 131 Marlowe, Steve, 553 Neu, Harold C., 319, 529, 687 Ripa, S., 666 Kim, H., 45 Marr, J. Joseph, 292 Neut, C., 764 Rohlfing, Stephen R., 301 King, John W., 770 Marsh, Y. Vivienne, 563 Nguyen, Khoi B., 455 Romanowski, Barbara, 455 Kingsbury, W. D., 373 Martin, Albert R., 626 Nicoletti, M., 9 Romaru, Annette, 618 Kirkpatrick, James, 7 Martinez, Octavio V., 358 Nierste, David M., 513 Romond, C., 764 Klein, Robert S., 292 Maruyama, Tsutomu, 385 Niles, Ann C., 368 Ronald, Allan R., 187 Klinger, Jeffrey D., 279 Maskell, Jeffrey P., 268 Noguchi, Takashi, 221 Roquet, F., 463 Knaus, Edward E., 476 Matsen, John M., 630 Northrop, Dexter B., 479 Rosano, Thomas G., 336 Knight, Paul R., 719 Matsui, Hidefumi, 221 Novick, William J., Jr., 380 Rosen, Barry P., 157 Knight, Vernon, 729 Matsumoto, Yoshimi, 98 Rosenberg, Martin, 622 Kobasa, William D., 683 Matthews, Thomas R., 563 Ober, Robert E., 301 Ross, Janette, 785 Koeppe, P., 105 Mattie, H., 263 Odio, Carla, 427, 556 Rotschafer, John C., 785 Kojo, Hitoshi, 98 Matzke, G. R., 128 Ogilvie, Richard I., 83 Rubin, Robert H., 626 Kolattukudy, Pappachan E., 173 Matzke, Gary R., 433, 603 Ohmae, Kenichi, 385 Ruggiero, Giuseppe, 182 Konno, Masatoshi, 754 McAnally, Thomas P., 422 Ohnishi, Haruo, 88 Rusconi, Franca, 395 Konopi6iska, Danuta, 134 McClatchey, Kenneth D., 491 Okafor, Josephine I., 413 Ryder, Neil S., 483 Kosuzume, Hiroshi, 88 McCormick, Ellen M., 336 29 9 Olsen, Kurt D., Sabados, Joyce, 646 Koyama, Masaru, 221 McCracken, George H., Jr., 2 Ooka, T., 242 427, 556 Saino, Yushi, 362 Kramer, Michael J., 729 Opal, Stephen, 7 Sakata, Yasutaka, 29 Kramer, William G., 62 McFarland, James W., 226 Otto, Michael J., 566 John H., 83 McGory, Robert W., 433 Sakuma, Takashi, 742 Kreeft, Overall, James C., Jr., 553 Salem, Nanda G., 603 Kueppers, Friedrich, 673 McGuirt, Paul V., 507 Overturf, Gary D., 258 Kunz, Samuel, 311 McHugh, Gail L., 586 Samuel, John, 476 McKeough, M. B., 10 Sandberg, Sverre, 354 Kuroki, Tohru, 146 Sanders, Christine C., 494 Kuwahara, Shogo, 98 McKerlie, M. Louese, 646 Panosian, Claire B., 655 Kwan, S., 382 McLafferty, Martha A., 65 Parker, Bruce C., 137 Sanders, W. Eugene, Jr., 494 Meatherall, Robert C., 306 Parr, Thomas R., Jr., 747 Sanfeliu, Isabel, 706 Labthavikul, Pornpen, 687 Meddens, M. J. M., 263 Parrillo, Patricia, 778 Saravolatz, Louis D., 377 Lacroix, Jean-Michel, 662 Mehta, Kapil, 366 Passarella, E., 760 Sattler, Fred R., 153 Lambe, Catherine U., 191 Mehta, R., 387 Pasticci, M. B., 666 Sawada, Takuo, 385 Lamothe, Francois, 662 Mehta, Reeta, 366 Patel, Indravadan H., 438 Sawai, Tetsuo, 148, 348 Larsson, A., 524 Mehta, R. J., 373 Pattison, Fred L. M., 455 Saxon, Barbara A., 630 Lastra, C. Fernandez, 458 Merigan, Thomas C., 25 Pattyn, Stefaan R., 518 Schaberg, Dennis R., 491 Lawee, David, 455 Merry, Joanne M., 339 Pauluzzi, S., 666 Scharpe, Simon L., 783 Lechi, A., 760 Meshnick, Steven R., 286 Pearson, Richard D., 571 Schelkly, W., 118 Lefler, Eli, 450 Metzger, Linda S., 216 Penn, Robert L., 770 Schentag, Jerome J., 201 Leguy, F., 638 Michel, M. F., 575 Penner, Brian, 306 Schiff, Jill B., 49 Leive, Loretta, 539 Miller, Heather, 411 Pennington, James E., 49 Schlepushkin, Anatoli N., 53 Lentino, Joseph R., 778 Miller, Richard L., 191 Perea, Evelio J., 342 Schnipper, Lowell E., 553 Leroy, A., 638 Miller, Wayne H., 191 Perna, Pasquale, 182 Schultz, Robert W., 201 Levi, Joe U., 358 Mills, K., 387 Perry, Helen C., 247 Schuppan, Dietrich, 301 Levison, Matthew E., 683 Mine, Yasuhiro, 98 Peters, Andre C. B., 522 Schuster, F. L., 109 VOL. 25, 1984 AUTHOR INDEX iii

Schwab, Bernard, 205 Stevens, David A., 450 Troke, Peter F., 483 Welage, Lynda S., 201 Sciavolino, Frank C., 113 Storrs, Bruce, 502 Trousdale, Melvin D., 522 Welch, David F., 212 Scribner, Ronald K., 212 Strikas, Raymond, 778 Tuazon, Carmelita U., 411 Wennersten, Christine, 398 Seidl, Gunther, 483 Stutman, Harris R., 212 Tung, Charlotte, 586 Wenzel, Richard P., 4 Selden, Robert F., 4 Sugerman, A. Arthur, 93 Tyrrell, D. Lorne, 476 Westmacott, Donald, 607 Seto, Kenji, 385 Sugihara, J. G., 438 Wexler, Hannah, 162 Shafer, W. M., 767 Sun, Chong-Son, 729 Ubukata, Kimiko, 754 Wiebe, Leonard I., 476 Shatzman, Allan R., 622 Sutphen, Nancy, 33 Ueno, Kazue, 131 Williams, J. David, 268 Shaw, James E., 507 Sutton, J. P., 37 Utili, Riccardo, 182 Williams, Peter E. O., 78, 344 Sherris, John C., 591 Swabb, Edward A., 93 Williamson, Peter J., 1 Shields, David S., 653 Swartz, Mark D., 586 Vaara, M., 701 Wilson, Katharine J., 139 Shigeta, Shiro, 515 Swartz, Morton N., 586 Valenta, J., 373 Wilson, Mary E., 626 Shikuma, Cecilia, 258 Szoka, Francis, 655 Van Caekenberghe, Dirk L., 518 Wilson, Samuel Z., 729 Shipley, Patricia L., 653 Van Etta, Linda L., 58 Wise, R., 612 Shlaes, David M., 527 Tagari, Gioula, 534 van Furth, R., 263 Wisseman, Charles L., Jr., 690 Siegel, Scott A., 566 Takafuji, Ernest, 7 Van Leeuwen, Willem B., 497 Wolfson, John S., 586 Siemsen, A. W., 438 Takahashi, Toshio, 385 van Raffe, M., 575 Wong, E. G. C., 438 Silver, Simon, 157 Tannenbaum, Charles S., 673 Van Schalkwijk, Wim P., 497 Woodbury, Charles, 7 Sirinavin, Sayomporn, 273 Tao, Pei-Zhen, 524 Van Wyk, Marieta, 344 Woods, D. R., 253 Slaney, Leslie A., 187 Taylor, Dean P., 622 Vaxelaire, Juliane, 311 Wright, Charlotte A., 408 Smith, C. W., 37 Telesetsky, Stephanie, 539 Velo, G. P., 760 Wright, Donald N., 165 Smith, Gaylord, 286 Terakado, Nobuyuki, 385 Verbist, Ludo, 141, 783 Wu, David H., 488 Smith, Margaret C. M., 446 TeStrake, Diane, 413 Verhaegen, Jan, 141 Wyde, Philip R., 729 Smith, Raymond P., 33, 488 Thearle, Patricia, 473 Verpooten, Gert A., 783 Wyler, David J., 655 Sobel, J. D., 281 Thomas, Marion L., 29, 427, 556 Viljanen, P., 701 Solberg, Claus O., 354 Thompson, J., 263 Vincent, P., 144 Yamaguchi, Akihito, 148, 348 Solliday, JoAnne, 532 Thompson, Robert L., 4 Visscher, David W., 513 Yamashita, Naoko, 754 Somerville, Peter J., 83 Thornsberry, C., 633 Visudhipan, Pongsakdi, 273 Yamashita, Toyoko S., 579 Sommers, De Klerk, 344 Thornsberry, Clyde, 392, 710 Vitvitski, L., 242 Yangco, Bienvenido G., 413 Sommers, H. M., 633 Threlkeld, Norma, 556 Vosbeck, Klaus, 735 Yano, Kuniichiro, 221 Sommers, Herbert M., 669 Ti, Teow-Yee, 83 Yeung, Tin-Chuen, 65 Southern, J. A., 253 Tidwell, Richard R., 582 Wagenvoort, Johan H. T., 497 Yoshinaga, Koji, 221 Sparling, P. F., 767 Tiemens, Karen M., 653 Walker, David H., 582 Yu, Victor L., 473 Spencer, G. R., 638 Tigaud, S., 144 Walker, Marion L., 502 Spruance, S. L., 10 Tocci, Michael J., 247 Walker, Naomi A., 513 Zaffaroni, Giuseppe, 395 Spruance, Spotswood L., 553 Tofte, Robert W., 532, 785 Walker, Richard I., 71 Zak, Oto, 311 St. Clair, Marty H., 191 Tolkoff-Rubin, Nina E., 626 Warnock, David W., 1 Zimmermann, Willy, 735 Stachowski, Michael, 778 Tramont, Edmund, 7 Watanabe, Kunitomo, 131 Zissis, Nicholas P., 534 Starr, S. E., 417 Trenholme, Gordon M., 504 Weinbaum, George, 673 Zorz6pulos, Jorge, 659 Steigbigel, Neal H., 375 Trepo, C., 242 Weinfeld, R. E., 438 Zuromskis, Peter, 626 Stern, Robert C., 579 Trevisan, Alejandro R., 659 Weiss, Emilio, 71 Zweig, Richard M., 16 SUBJECT INDEX VOLUME 25

AC-1370 immunology, 93 mechanism of action, 88 combinations P. aeruginosa pneumonia, 49 phagocyte functions, 88 gentamicin, 408 pediatric patients, 212 Acanthamoeba spp. comparative efficacy syphilis, 390 phenothiazone compounds, 109 , 643 Acridine orange S. faecalis endocarditis, 408 K. pneumoniae R plasmid deletion, 659 shigellosis, 643 Bacillus megaterium Acyclic nucleosides Anaerobic bacteria copper toxicity, 650 9-(1,3-dihydroxy-2-propoxymethyl) apalcillin, 162 siderophores, 650 guanine, 563 , 764 Acyclovir , 162 coagulase-negative staphylococci, 502 antiviral-activity potentiation ciprofloxacin, 342 S. aureus nasal carriers, 422 polyene macrolides, 772 clindamycin, 764 Bacterial infections efficacy, 10 erythromycin, 529 , 510 herpes simplex virus, 10 metronidazole, 764 Bacteriocins DNA fragment synthesis, 507 RU 28965, 529 B. fragilis, 253 patient-initiated treatment, 553 Animal viruses Bacteroides fragilis penetration, 10 halothane, 719 bacteriocins, 253 synergy with interferon, 515 replication, 719 topical therapy, 10 Antifungal agents 7a-methoxy, 131 varicella-zoster virus, 515 Aspergillus spp., 560 7p-methoxyiminoacetamido, 131 Adenine arabinoside combinations , 662 synergy with interferon, 515 amphotericin B, 560 P-lactams, 662 varicella-zoster virus, 515 rifampin, 560 synergy with gentamicin Aerobic bacteria Antifungal azoles clindamycin, 71 erythromycin, 529 Bay 1 9139, 339 metronidazole, 71 RU 28965, 529 Bay n 7133, 339 , 71 Amikacin Antineoplastic agents Bacteroides melaninogenicus combinations screening synergy with gentamicin , 725 E. coli genetically modified strain, 622 clindamycin, 71 , 725 Antiviral compounds metronidazole, 71 , 725 varicella-zoster virus susceptibility, 417 penicillin, 71 cystic fibrosis, 279 Apalcillin Basidiobolus spp. P. aeruginosa, 279 anaerobes, 162 susceptibility, 413 P. cepacia, 279 comparative activity, 162 Bay 1 9139 Enterobacteriaceae, 725 , 669 antifungal activity, 339 nephrotoxicity, 168 , 669 Bay n 7133 neutropenic-site rabbit model, 545 pharmacokinetics antifungal activity, 339 P. aeruginosa, 545 compared with piperacillin, 105 high-pressure liquid chromatography, tubular reabsorption, 168 1-,-D-Arabinofuranosyl-E-5-(2-bromovin- 596 Aminoglycosides yl)uracil Bay o 9867 combinations varicella-zoster virus, 742 see ciprofloxacin teichomycin, 411 Arsenate , 411 E. coli R factors, 157 probenecid interaction, 676 enterococci, 411 Aspergillus spp. Biliary tract disease extraction from renal cortical tissue, 783 amphotericin B, 560 excretion, 358 modification by enzymes antifungal agents, 560 Biophotometric methods S. aureus, 754 rifampin, 560 S. aureus intraphagocytic activity, 735 S. epidermidis, 754 Bordetella pertussis nephrotoxicity, 168 comparative efficacy, 49 degraded strains, 537 2"-O-nucleotidyltransferase activity, 234 neutropenic-site rabbit model, 545 resistance, 537 P. aeruginosa, 488, 534 P. aeruginosa Bromovinyl deoxyuridine rat tissue drug combinations, 545 synergy with interferon, 515 enzyme immunoassays, 497 pneumonia, 49 varicella-zoster virus, 515 resistance, 234 pharmacokinetics (E)-5-(2-Bromovinyl)-2'-deoxyuridine staphylococci, 411 cystic fibrosis, 630 herpes simplex virus polypeptide syn- synergy with 13-lactams, 534 Aztreonam thesis, 566 tubular reabsorption, 168 activity BW7S9U alone, 212 DNA polymerases combined with clavulanic acid, 276 in combination, 212 cellular a, 191 urinary tract infections, 276, 626 biliary tract disease, 358 herpes simplex virus induced, 191 Amphotericin B combinations triphosphate, 191 antifungal activity, 387 amikacin, 279 Aspergillus spp., 560 cystic fibrosis, 279 C. albicans infection, 366 gram-negative bacilli, 283 Campylobacter fetus subsp. jejuni combinations 3-lactams, 283 metronidazole, 145 antifungal agents, 560 multiple resistance, 283 niridazole, 145 rifampin, 560 P. aeruginosa, 279 Campylobacter spp. leishmaniasis, 655 P. cepacia, 279 ciprofloxacin, 504 liposome encapsulated, 366, 387, 655 comparative efficacy, 49 Candida albicans prophylaxis, 366 excretion, 358 amphotericin B, 366 iv VOL. 25, 1984 SUBJECT INDEX v

clotrimazole, 450 Ceftazidime econazole, 450 combinations FK 027, 98 growth, 483 amikacin, 725 Chancroid ketoconazole, 281, 450 clindamycin, 657 H. ducreyi, 187 miconazole, 450 gentamicin, 725 tetracycline resistance, 187 naftifine, 483 distribution in ascitic fluid, 760 Chlamydia trachomatis neutropenic mice, 366 Enterobacteriaceae, 725 cinoxacin, 123 sterol biosynthesis, 483 H. influenzae, 29 ciprofloxacin, 123 susceptibility meningitis nalidixic acid, 123 growth phase, 316 efficacy, 29 norfloxacin, 123 ketoconazole, 316 pharmacokinetics, 29 pipemidic acid, 123 miconazole, 316 nephrotoxicity in rats, 513 Chloramphenicol tioconazole, 450 P. aeruginosa mutants, 382 antagonism of 3-lactams, 405 vaginitis, 281 pharmacokinetics comparative activity, 327 Candida spp. decreased renal function, 785 detection, 205 peptide transport, 373 meningitis, 29 enzyme-linked immunoassay, 205 polyoxin, 373 normal subjects, 638 K. pneumoniae, 405 derivatives renal insufficiency, 201 quantitation, 205 SF2103A, 348 uremic subjects, 638 Salmonella spp., 327 Carbenicillin Pseudomonas spp., 395 Chlorpromazine comparative activity urinary tract infections, 395 hydrochloride apalcillin, 669 Ceftizoxime pathogenic amoebae, 109 piperacillin, 669 combinations L. donovani, 571 hemostasis, 153 amikacin, 725 Cinoxacin Cardiopulmonary bypass surgery gentamicin, 725, 770 antibacterial activity, 633 ceftriaxone levels, 37 Enterobacteriaceae, 725 cross-resistance high-pressure liquid chromatography, DJ6783, 775 cross-resistance 336 enoxacin, 775 , 666 meningitis, 258 nalidixic acid, 775 E. coli neutropenic-site rabbit model, 545 norfloxacin, 775 killing, 182 P. aeruginosa, 545, 770 oxolinic acid, 775 phagocytosis, 182 uremic patients, 336 C. trachomatis, 123 Ceftriaxone resistant-population selection, 775 urinary excretion amikacin, 725 Ciprofloxacin furosemide, 618 combinations anaerobic bacteria, 342 piretanide, 618 gentamicin, 725 antibacterial activity, 633 water loading, 618 Enterobacteriaceae, 725 Campylobacter spp., 504 Cefmenoxime H. influenzae, 29 comparative activity, 319, 331, 518 serious bacterial infections, 510 kinetic disposition C. trachomatis, 123 renal failure patients, 83 enteric pathogens, 504 penetration into surgical-wound drain- levels in blood and tissue inoculum effect, 342 age, 473 cardiopulmonary bypass surgery, 37 medium effect, 342 meningitis pH effect, 342 S. aureus endocarditis, 16 efficacy, 29, 40 Citrobacter spp. pharmacokinetics resistance, 591 kinetics meningitis, 29 Clavulanic acid effects of protein binding, 58 renal impairment, 438 combined with amoxicillin susceptibility, 377 urinary tract infections, 276 1-acetoxyethyl ester, 78 combined with , 392 comparative efficacy axetil ,-lactam activity, 662 cephalothin, 778 pharmacokinetics, 344 Clindamycin dihydrochloride meningitis, 273 anaerobic bacteria, 764 placental transfer, 147 Cephalosporinases combined with ceftazidime skin infections, 778 P. maltophilia, 362 antibacterial activity, 657 soft tissue infections, 778 Cephalosporins comparative activity Cefoxitin aminothiazolyl a-methoxyimino, 710 cefoxitin, 764 anaerobic bacteria, 764 B. fragilis, 131 synergy comparative activity cross-resistance Bacteroides spp., 71 clindamycin, 764 cefamandole, 666 gentamicin, 71 metronidazole, 764 methicillin, 666 Clotrimazole neutropenic-site rabbit model, 545 expanded spectrum C. albicans, 450 P. aeruginosa, 545 SK&F 88070, 694 Cefpiramide HR810, 710 staphylococcal endocarditis, 311 anaerobes, 162 7a-methoxy, 131 Common cold comparative activity, 162 7p-methoxyiminoacetamido, 131 zinc gluconate, 20 pharmacokinetics resistance Conidiobolus spp. humans, 221 Citrobacter spp., 591 susceptibility, 413 Cephalothin Contact-blocking virus inhibitor cystic fibrosis, 4 comparative efficacy size, 646 P. aeruginosa mutants, 382 cefotiam, 778 stability, 646 pharmacokinetics Enterobacteriaceae resistance, 725 Copper cystic fibrosis, 579 skin infections, 778 B. megaterium, 560 single dose, 579 soft tissue infections, 778 toxicity vi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

siderophores, 560 Enteric pathogens Fludalanine Coumermycin ciprofloxacin, 504 pentizidone combination antibacterial activity, 687 Enterobacter aerogenes comparative activity, 612 Cystic fibrosis endocarditis Flumequine amikacin, 279 gentamicin, 683 fluorometric assays, 301 azlocillin pharmacokinetics, 630 , 683 high-pressure liquid chromatography, aztreonam, 279 ticarcillin, 683 301 cefsulodin Enterobacteria microbiological assays, 301 pharmacokinetics, 579 P-lactamases, 268 Fluorinated piperazinyl-substituted quino- sodium, 4 Enterobacteriaceae line derivatives P. aeruginosa, 279 amikacin, 725 comparative activity, 518 P. cepacia, 279 ceftazidime, 725 Fluorometric assays piperacillin, 279 ceftizoxime, 725 flumequine, 301 ticarcillin, 279 ceftriaxone, 725 Furosemide Cytomegalovirus cephalothin resistant, 725 cefazolin excretion in urine, 618 a-interferon, 25 gentamicin, 725 2'-nor-2'-deoxyguanosine, 247 Enterococci retinitis, 25 aminoglycosides, 411 Gentamicin ribosomal resistance, 398 coagulase-negative staphylococci, 502 rifampin, 411 combinations Desferrioxamine streptomycin, 398 ampicillin, 408 urinary tract isolates, 375 susceptibility, 532 ceftazidime, 725 cis-Diammineplatinum[II]-polyglutamic teichomycin, 411 ceftizoxime, 725, 770 acid vancomycin, 411 ceftriaxone, 725 T. congolense, 286 Enzyme immunoassays mezlocillin, 408 Dibekacin aminoglycosides E. coli nephrotoxicity, 168 rat tissue, 497 killing, 182 tubular reabsorption, 168 Enzyme-linked immunoassays phagocytosis, 182 9-(1,3-Dihydroxy-2-propoxymethyl) competitive elimination rate, 128 guanine chloramphenicol, 205 clearance, 128 herpes simplex virus, 563 Enzymes Enterobacteriaceae, 725 ,-interferon, 563 aminoglycoside modification, 754 hemodialysis, 128 DJ6783 S. aureus, 754 nephrotoxicity, 168 cross-resistance S. epidermidis, 754 P. aeruginosa, 770 cinoxacin, 775 Erysipelas synergy enoxacin, 775 swine B. fragilis, 71 nalidixic acid, 775 E. rhusiopathiae resistance, 385 B. melaninogenicus, 71 norfloxacin, 775 Erysipelothrix rhusiopathiae clindamycin, 71 oxolinic acid, 775 chronic swine erysipelas, 385 metronidazole, 71 resistant-population selection, 775 resistance, 385 penicillin, 71 DNA gyrase inhibitors Erythromycin tubular reabsorption, 168 E. coli plasmid elimination, 586 aerobic bacteria, 529 Gonorrhea DNA polymerases anaerobic bacteria, 529 rosoxacin, 455 BW759U triphosphate, 191 comparative activity, 529 Gram-negative bacteria cellular a, 191 methylmalonyl-coenzyme A source, 173 aztreonam, 283 hepatitis virus, 242 synthesis from S. erythreus, 173 ,B-lactams, 283 herpes simplex virus induced, 191 Escherichia coli multiple resistance, 283 Doxycycline cefamandole, 182 B nonapeptide, 701 polymorphonuclear leukocytes, 354 DNA gyrase inhibitors, 586 Granulocytes DNA repair mutants, 65 S. sanguis endocarditis, 263 genetically modified strain stimulation Econazole antineoplastic-agent screening, 622 , 179 C. albicans, 450 gentamicin, 182 MK 0791, 179 Endocarditis killing, 182 ampicillin, 408 meningitis Haemophilus ducreyi ceforanide, 16 mezlocillin pharmacokinetics, 427 chancroid treatment, 187 cloxacillin, 311 metronidazole, 65 1-lactamase plasmid, 296 drug abusers, 16 novobiocin, 586 resistance gentamicin, 408 outer membrane permeability, 539 plasmid mediated, 187 granulocytes, 263 phagocytosis, 182 tetracycline, 187 mezlocillin, 408 plasmid elimination, 586 Haemophilus influenzae S. aureus, 16 pMG110, 586 multiply resistant S. faecalis, 408 R factors susceptibility, 706 S. sanguis, 263 arsenate, 157 type b staphylococcal, 311 homology, 157 ceftazidime, 29 Enoxacin tetracyclines, 539 ceftriaxone, 29 cross-resistance tetracycline transport, 446 chloramphenicol resistant, 29 cinoxacin, 775 Exopolysaccharides imipenem, 29 DJ6783, 775 P. aeruginosa 3-lactams, 747 nalidixic acid, 775 binding, 673 mechanisms of resistance, 747 norfloxacin, 775 meningitis, 29 oxolinic acid, 775 FK 027 Halothane resistant-population selection, 775 antibacterial properties, 98 animal virus replication, 719 VOL. 25, 1984 SUBJECT INDEX vii

Heavy-metal salts H. influenzae, 29 SF2103A, 348 susceptibility imipenem resistance, 491 ,-Lactams M. avium, 137 meningitis antagonism by chloramphenicol, 405 M. intracellulare, 137 efficacy, 29 B. fragilis M. scrofulaceum, 137 pharmacokinetics, 29 clavulanic acid, 662 Hemodialysis methicillin resistance combinations gentamicin S. aureus, 491 aztreonam, 283 clearance, 128 P. vulgaris P-lactamase, 149 gram-negative bacilli, 283 elimination rate, 128 subinhibitory concentrations, 491 multiple resistance, 283 tobramycin Influenza virus H. influenzae type b clearance, 128 inhibition mechanism of resistance, 747 elimination rate, 128 interferon, 53 K. pneumoniae, 405 Hemostasis ribavirin, 53 P. aeruginosa, 488, 534 carbenicillin, 153 rimantadine hydrochloride, 53 synergy with aminoglycosides, 534 mezlocillin, 153 Inosine analogs combinations, 142 placebo, 153 Leishmania spp., 292 Lankacidin group Hepatitis virus Trypanosoma spp., 292 side chain modifications, 226 DNA polymerases, 242 Interferon Leishmania donovani human, 242 aerosolized, 729 chlorpromazine, 571 woodchuck, 242 clearance, 729 Leishmaniasis Herpes labialis cytomegalovirus retinitis, 25 amphotericin B, 655 acyclovir, 553 9-(1,3-dihydroxy-2-propoxymethyl) Leishmania spp. patient-initiated treatment, 553 guanine, 563 inosine analogs, 292 Herpes simplex virus herpes simplex virus, 563 Listeria monocytogenes acyclovir human leukocyte, 515 meningitis DNA fragment synthesis, 507 influenza virus inhibition, 53 mezlocillin pharmacokinetics, 427 efficacy, 10 pulmonary deposition, 729 Lithium penetration, 10 synergy herpes simplex virus topical therapy, 10 acyclovir, 515 cell cultures, 522 (E)-5-(2-bromovinyl)-Z'-deoxyuridine, adenine arabinoside, 515 latent-infection reactivation in rab- 566 bromovinyl deoxyuridine, 515 bits, 522 BW759U triphosphate, 191 phosphonoformic acid, 515 9-(1,3-dihydroxy-2-propoxymethyl) Intraphagocytic activity guanine, 563 biophotometric method, 735 DNA polymerase induction, 191 S. aureus, 735 Meningitis p-interferon, 563 (E)-5-(2-Iodovinyl)-2'-deoxyuridine ceftazidime, 29 (E)-5-(2-iodovinyl)-2'-deoxyuridine up- herpes simplex virus, 476 ceftizoxime, 258 take, 476 uptake, 476 ceftriaxone, 29, 40 lithium cefuroxime, 273 cell cultures, 522 Kanamycin E. coli, 427 latent-infection reactivation in rab- acetyltransferase imipenem, 29 bits, 522 enzymatic modification, 479 L. monocytogenes, 427 2'-nor-2'-deoxyguanosine, 238 resistance, 479 mezlocillin pharmacokinetics, 427 orofacial infections in mice, 238 VmaxlKm ratio, 479 traditional therapy, 40 polypeptide synthesis, 566 Ketoconazole Methicillin SK&F 21681, 195 C. albicans cross-resistance thymidine kinase growth phase, 316 cefamandole, 666 guanosine analogs, 524 inhibition, 450 cephalosporins, 666 High-pressure liquid chromatography killing, 450 resistance Bay n 7133, 596 susceptibility, 316 imipenem, 491 ceftizoxime, 336 vaginitis, 281 S. aureqs, 491 flumequine, 301 pharmacokinetics Methylmalonyl-coenzyme A Sch 28191 levels, 45 influence of food, 1 erythromycin synthesis, 173 HR810 Klebsiella pneumoniae S. erythreus, 173 evaluation, 710 chloramphenicol, 405 1-Methyl-5-thiotetrazole Hypoprothrombinemia P-lactams, 405 hypoprothrombinemia, 380 1-methyl-5-thiotetrazole, 380 R plasmids Metronidazole moxalactam, 380 anaerobic bacteria, 764 acridine orange, 659 C. fetus subsp. jejuni, 145 deletions, 659 comparative activity Imidazoles cefoxitin, 764 C. albicans, 450 3-Lactamases E. coli DNA repair mutants, 65 clotrimazole, 450 enterobacteria, 268 pharmacokinetics econazole, 450 H. ducreyi, 296 peritoneal dialysis patients, 306 ketocanazole, 450 inactivation, 348 synergy miconazole, 450 mezlocillin-resistant S. aureus Bacteroides spp., 71 tioconazole, 450 cell bound, 125 gentamicin, 71 Imipenem extracellular, 125 Mezlocillin bioactivity N. gonorrhoeae, 296 combinations medium, 781 P. aeruginosa mutants, 382 gentamicin, 408, 683 temperature, 781 PSE-2, 268 E. aerogenes endq~zarditis, 683 time, 781 P. vulgaris E. coli, 427 granulocyte function stimulation, 179 imipenem, 149 hemostasis, 153 viii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

L. monocytogenes, 427 Nocardicin A ceftazidime pharmacokinetics synergy decreased renal function, 785 meningitis, 427 L-norvalyl-L-1-aminoethylphosphonic H. influenzae meningitis, 29 newborn infants, 556 acid, 105 normal subjects, 638 pediatric oncology patients, 62 2'-Nor-2'-deoxyguanosine renal insufficiency, 201 S. aureus resistance cytomegalovirus, 247 uremic subjects, 638 ,-lactamase, 125 herpes simplex virus, 238 ceftriaxone S. faecalis endocarditis, 408 Norfloxacin H. influenzae meningitis, 29 Miconazole antibacterial activity, 633 renal impairment, 438 C. albicans cross-resistance , 344 growth phase, 316 cinoxacin, 775 imipenem, 29 inhibition, 450 DJ6783, 775 ketoconazole, 1 killing, 450 enoxacin, 775 metronidazole, 306 susceptibility, 316 nalidixic acid, 775 mezlocillin Microbiological assays oxolinic acid, 775 meningitis, 427 flumequine, 301 C. trachomatis, 123 newborn infants, 556 Minocycline resistant-population selection, 775 pediatric oncology patients, 62 polymorphonuclear leukocytes, 354 L-Norvalyl-L-1-aminoethylphosphonic moxalactam, 33 MK 0791 acid piperacillin, 105 granulocyte function stimulation, 179 synergy , 599 Moxalactam nocardicin A, 607 vancomycin hypoprothrombinemia, 380 Novobiocin peritoneal dialysis, 603 pharmacokinetics E. coli plasmid elimination, 586 renal insufficiency, 433 elderly subjects, 33 2"-O-Nucleotidyltransferase Phenothiazone Fompounds Mycobacterium avium activity-aminoglycoside resistance rela- chlorpromazine hydrochloride, 109 susceptibility tion, 234 inhibition of pathogenic amoebae, 109 heavy-metal salts, 137 trifluoperazine dihydrochloride, 109 oxyanions, 137 Oleandomycin Phosphomycin Mycobacterium intracellulare derivatives pleural effusion patients, 458 suspectibility Phosphonoformic acid heavy-metal biological activity, 113, 118 salts, 137 synthesis, 113 synergy with interferon, 515 oxyanions, 137 Osteomyelitis varicella-zoster virus, 515 Mycobacterium scrofulaceum Pipemidic acid susceptibility vancomycin concentrations C. trachomatis, 123 heavy-metal salts, 137 in rabbit serum, 140 Piperacillin oxyanions, 137 coagulase-negative staphylococci, 502 combinations Oxolinic acid amikacin, 279 cystic fibrosis, 279 Naegleria fowleri antibacterial activity, 633 cross-resistance P. aeruginosa, 279 phenothiazone compounds, 109 P. 279 Naftifine cinoxacin, 775 cepacia, DJ6783, 775 comparative activity C. albicans, 483 apalcillin, 669 Nalidixic acid enoxacin, 775 nalidixic acid, 775 carbenicillin, 669 antibacterial activity, 633 comparative 49 cross-resistance norfloxacin, 775 efficacy, resistant-population selection, 775 P. aeruginosa cinoxacin, 775 Oxyanions mutants, 382 DJ6783, 775 pneumonia, 49 enoxacin, 775 susceptibility M. avium, 137 pharmacokinetics norfloxacin, 775 compared with apalcillin, 105 oxolinic acid, 775 M. intracellulare, 137 M. scrofulaceum, 137 susceptibility, 377 C. trachomatis, 123 Oxytetracycline Piretanide resistant-population selection, 775 polymorphonuclear cefazoline excretion in humans, 618 Neisseria gonorrhoeae leukocytes, 354 Pivmecillinam envelope mutations comparative efficacy susceptibility, 767 Pediatric patients ampicillin, 643 env-10, 767 aztreonam activity, 212 shigellosis, 643 pyocin resistance, 767 Pefloxacin mesylate Placebo ,B-lactamase plasmid, 2% absorption, 463 hemostasis, 153 probenecid, 676 distribution, 463 Plasmids resistance trends, 7 elimination, 463 DNA gyrase inhibitors, 586 Neisseria meningitidis metabolic fate, 463 E. coli(pMG110), 586 nasopharyngeal carriers, 494 Penicillin novobiocin, 586 Sch 29,482, 494 synergy resistance Nephrotoxicity Bacteroides spp., 71 acridine orange, 659 aminoglycosides, 168 gentamicin, 71 deletions, 659 tubular reabsorption, 168 Pentizidone host range, 289 Netilmicin fludalanine combination K. pneumoniae, 659 nephrotoxicity, 168 comparative activity, 612 streptococcal macrolide, 289 tubular reabsorption, 168 Pharmacokinetics S. wien epidemic history, 499 Niridazole apalcillin, 105 Pleural effusion C. fetus subsp. jejuni, 145 azlocillin, 607 phosphomycin, 458 Nocardia asteroides cefpiramide, 221 Pneumonia susceptibility, 165 cefsulodin, 579 azlocillin, 49 ix VOL. 25, 1984 SUBJECT INDEX

aztreonam, 49 Resistance Sparsomycin P. aeruginosa, 49 N. gonorrhoeae, 7 nontoxic analogs piperacillin, 49 Retinitis hydrophobic sulfoxide substituent, ticarcillin, 49 cytomegalovirus, 25 443 tobramycin, 49 a-interferon, 25 puromycin, 443 Polyene macrolides R factors Staphylococci acyclovir activity, 772 E. coli aminoglycosides, 411 Polymorphonuclear leukocytes arsenate, 157 cloxacillin, 311 doxycycline, 354 homology, 157 coagulase negative minocycline, 354 Ribavirin bacitracin, 502 oxytetracycline, 354 influenza virus inhibition, 53 gentamicin, 502 nonapeptide Rickettsia rickettsii oxacillin, 502 gram-negative bacteria, 701 cell injury, 582 streptomycin, 502 Polyoxin protease inhibitors, 582 vancomycin, 502 anti-Candida activity, 373 Rifampin endocarditis, 311 peptide transport, 373 Aspergillus spp., 560 rifampin, 411 Probenecid combinations teichomycin, 411 benzylpenicillin interaction, 676 amphotericin B, 560 vancomycin, 411 N. gonorrhoeae, 676 antifungal agents, 560 Staphylococcus aureus Protease inhibitors teichomycin, 411 aminoglycoside-modifying enzyme, 754 amidine type, 582 vancomycin, 411 biophotometric method, 735 R. rickettsii, 582 enterococci, 411 ceforanide, 16 Protein binding S. aureus nasal carriers, 422 endocarditis, 16 cefotaxime kinetics, 58 staphylococci, 411 intraphagocytic activity, 735 Proteus vulgaris Rimantadine hydrochloride mezlocillin resistance 1-lactamase influenza virus inhibition, 53 P-lactamase, 125 imipenem, 149 Rochalimaea quintana nasal carriers susceptibility patterns, 690 bacitracin, 422 amikacin, 279, 545 trench fever, 690 rifampin, 422 aminoglycosides, 488, 534 Rosoxacin resistance azlocillin, 49, 545 gonorrhea, 455 imipenem, 491 aztreonam, 49, 279 RU 28965 methicillin, 491 cefoxitin, 545 aerobic bacteria, 529 tolerance detection, 571 cefsulodin, 382 anaerobic bacteria, 529 Staphylococcus epidermidis ceftazidime, 382 comparative activity, 529 aminoglycoside-modifying enzyme, 754 ceftizoxime, 545, 770 Streptococci cystic fibrosis, 279 resistance plasmids, 289 exopolysaccharide Streptococcus faecalis binding, 673 Salmonella spp. ampicillin, 408 gentamicin, 770 chloramphenicol, 327 gentamicin, 408 P-lactamase, 382 Salmonella wien endocarditis, 408 P-lactams, 488, 534 epidemic history, 499 mezlocillin, 408 mutants, 382 plasmid stability, 499 Streptococcus sanguis neutropenic-site rabbit model, 545 Sch 28191 endocarditis, 263 piperacillin, 49, 279, 382 high-pressure liquid chromatography, granulocytes, 263 pneumonia, 49 45 vancomycin resistance, 527 ticarcillin, 49, 279 levels in biological fluids, 45 Streptomyces erythreus tobramycin, 49 Sch 29,482 erythromycin synthesis, 173 Pseudomonas cepacia N. meningitidis nasopharyngeal carri- methylmalonyl-coenzyme A, 173 amikacin, 279 ers, 494 Streptomyces fradiae aztreonam, 279 SF2103A carbon incorporation cystic fibrosis, 279 3-lactamase inactivation, 348 tylactone, 216 piperacillin, 279 Shigella flexneri Streptomycin ticarcillin, 279 sulfamethoxazole-trimethoprim resist- coagulase-negative staphylococci, 502 Pseudomonas maltophilia ance, 653 enterococci, 398 cephalosporinase, 362 Shigellosis ribosomal resistance, 398 Pseudomonas spp. ampicillin, 643 Sulfamethoxazole ceftazidime, 395 pivmecillinam, 643 combined with trimethoprim, 653 urinary tract infections, 395 Siderophores Sulfamethoxazole-trimethoprim Pyocins B. megaterium, 560 S. flexneri resistance, 653 N. gonorrhoeae resistance, 767 copper toxicity enhancement, 560 Sultamicillin SK&F 21681 pharmacokinetics, 599 herpes simplex virus, 191 Surgical wounds Quinolone carboxylic acid compounds SK&F 88070 cefoperazone penetration, 473 ciprofloxacin, 319, 331 antimicrobial activity, 694 Syphilis Skin infections aztreonam, 390 Renal enzyme inhibitors cefotiam, 778 MK 0791, 179 cephalothin, 778 Teichomycin Renal insufficiency SM-1652 combinations pharmacokinetics see cefpiramide aminoglycosides, 411 ceftazidime, 201 Soft tissue infections rifampin, 411 ceftriaxone, 438 cefotiam, 778 enterococci, 411 vancomycin, 433 cephalothin, 778 staphylococci, 411 x SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Temocillin Trench fever Vancomycin combined with other 3-lactams, 142 R. quintana coagulase-negative staphylococci, 502 Tetracyclines susceptibility patterns, 690 combinations chancroid treatment, 187 Trifluoperazine dihydrochloride aminoglycosides, 411 doxycycline, 354 pathogenic amoebae, 109 rifampin, 411 E. coli outer membrane permeability, Trimethoprim enterococci, 411 539 combined with sulfamethoxazole, 653 osteomyelitis H. ducreyi resistance, 187 Trypanosoma congolense concentrations in rabbit serum, 140 hydrophobicity, 539 cis-diammineplatinum[II]-poly-glutam- pharmacokinetics minocycline, 354 ic acid, 286 peritoneal dialysis, 603 oxytetracycline, 354 Trypanosoma spp. renal insufficiency, 433 polymorphonuclear leukocytes, 354 inosine analogs, 292 S. sanguis resistance, 527 transport into E. coli, 446 Tuftsin staphylococci, 411 Ticarcillin analogs, 134 Varicella-zoster virus combinations antibacterial properties, 134 acyclovir, 515 amikacin, 279 Tylactone adenine arabinoside, 515 clavulanic acid, 392 carbon incorporation 1-0-D-arabinofuranosyl-E-5-(2-bromo- cystic fibrosis, 279 amino acid derived, 216 vinyl)uracil, 742 gentamicin, 683 S. fradiae, 216 bromovinyl deoxyuridine, 515 P. aeruginosa, 279 interferon, 515 P. cepacia, 279 U-63196E phosphonoformic acid, 515 comparative efficacy, 49 comparative activity, 401 susceptibility, 417 E. aerogenes endocarditis, 683 Urinary tract infections P. aeruginosa pneumonia, 49 amoxicillin, 626 Tioconazole amoxicillin-clavulanic acid, 276 C. albicans, 450 ceftazidime, 395 WIN 49375 Tobramycin desferrioxamine, 375 susceptibility, 377 clearance, 128 Pseudomonas spp., 395 comparative efficacy, 49 elimination rate, 128 hemodialysis, 128 Vaginitis Zinc gluconate P. aeruginosa pneumonia, 49 C. albicans, 281 common cold, 20 susceptibility, 377 ketoconazole, 281 double-blind study, 20 1984 APPLICATION FOR FULL MEMBERSHIP IN THE AMERICAN SOCIETY FOR MICROBIOLOGY 1913 1 Street, NW * Washington, DC 20006 * (202) 833-9680 COMPLETE ALL INFORMATION REQUESTED AND RETURN FORM WITH REMITTANCE IN U.S. FUNDS Eligibility ASM welcomes to full membership anyone who is interested in its objectives and has a minimum of a bachelors de- gree or equivalent in microbiology ora related field. Initiation Memberships are initiated and renewed in January each year. Unless there are directions to the contrary, membership nominations received prior to November 1 are credited to the current year, and back issues of the selected publications for the current year are fumished, if available. Nominations received after November 1 will become effective the following January. NAME FIRST INITIAL LAST ADDRESS CITY STATE/PROVINCE ZIP/POSTAL CODE COUNTRY PHONENUMBER( ) YEAROFBIRTH SEX_ HIGHEST DEGREE YEAR EARNED MAJOR SUBJECT GRANTING INSTITUTION PRESENT POSITION CURRENT SCIENTIFIC AREA SIGNATURE DATE *NOMINATED BY SIGNATURE OF ASM MEMBER *If you are not associated with an ASM nominating member, you can still send in this full member application form and we will contact you.

Dues Annual dues for 1984 are $50.00, with $5.00 allocated for ASM News and $4.00 for membership services. Apply the remaining $41.00 to subscriptions for the ASM journals at the special membership rates indicated below. Joumals Please check: El Enclosed is my dues payment (in U.S. dollars only) ...... $50 El Please send me the following ASM journal(s) at Member Price(s): U.S. Non-U.S. Amount Antimicrobial Agents and Chemotherapy $31 $41 $ Applied and Environmental Microbiology 32 42 Molecular and Cellular Biology 27 35 Infection and Immunity 37 49 International Journal of Systematic Bacteriology 27 27 Journal of Bacteriology 37 49 Journal of Clinical Microbiology 31 41 Journal of Virology 37 49 Microbiological Reviews 16 26 Total Joumal Fees $ Subtract your $41 Member Journals Credit $ -41

Subtotal (if less than zero, enter zero) $ S Add your $50 Mombership Dues $ +50 Total (Dues plus Journals). If total is less than $50.00, enter $50.00 $ S PAYMENT IN U.S. DOLLARS MUST ACCOMPANY APPLICATION A membership card, voting registration form, Placement Committee form and the journal(s) of your choice will be sent within 90 days upon completion of processing. Dues for individual membership in ASM are tax deductible. Rates are for 1 984 only. Non-U.S. applicants remit in U.S. dollars by check or draft payable to ASM through a U.S. bank located within the Continental U.S. Applicants from Canada may use check made out in U.S. dollars and drawn on a Canadian bank. U.S. and non-U.S. applicants may choose to pay with VISA or MasterCard. If that is your preference, please fill in the box below.

VISA * O MASTERCARD # EXPIRATION DATE TODAY'S DATE SIGNATURE .- Minimum Charge $15.00